Xanthine-based KMUP-1 improves HDL via PPARγ/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss

The phosphodiesterase inhibitor (PDEI)/eNOS enhancer KMUP-1, targeting G-protein coupled receptors (GPCRs), improves dyslipidemia. We compared its lipid-lowering effects with simvastatin and explored hormone-sensitive lipase (HSL) translocation in hepatic fat loss. KMUP-1 HCl (1, 2.5, and 5 mg/kg/da...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Kung-Kai, Wu, Bin-Nan, Liu, Chung-Pin, Yang, Tzu-Yang, Kao, Li-Pin, Wu, Jiunn-Ren, Lai, Wen-Ter, Chen, Ing-Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Biochemistry and Molecular Biology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617394/
https://www.ncbi.nlm.nih.gov/pubmed/26351364
http://dx.doi.org/10.1194/jlr.M057547
_version_ 1782396787819020288
author Kuo, Kung-Kai
Wu, Bin-Nan
Liu, Chung-Pin
Yang, Tzu-Yang
Kao, Li-Pin
Wu, Jiunn-Ren
Lai, Wen-Ter
Chen, Ing-Jun
author_facet Kuo, Kung-Kai
Wu, Bin-Nan
Liu, Chung-Pin
Yang, Tzu-Yang
Kao, Li-Pin
Wu, Jiunn-Ren
Lai, Wen-Ter
Chen, Ing-Jun
author_sort Kuo, Kung-Kai
collection PubMed
description The phosphodiesterase inhibitor (PDEI)/eNOS enhancer KMUP-1, targeting G-protein coupled receptors (GPCRs), improves dyslipidemia. We compared its lipid-lowering effects with simvastatin and explored hormone-sensitive lipase (HSL) translocation in hepatic fat loss. KMUP-1 HCl (1, 2.5, and 5 mg/kg/day) and simvastatin (5 mg/kg/day) were administered in C57BL/6J male mice fed a high-fat diet (HFD) by gavage for 8 weeks. KMUP-1 inhibited HFD-induced plasma/liver TG, total cholesterol, and LDL; increased HDL/3-hydroxy-3-methylglutaryl-CoA reductase (HMGR)/Rho kinase II (ROCK II)/PPARγ/ABCA1; and decreased liver and body weight. KMUP-1 HCl in drinking water (2.5 mg/200 ml tap water) for 1–14 or 8–14 weeks decreased HFD-induced liver and body weight and scavenger receptor class B type I expression and increased protein kinase A (PKA)/PKG/LDLRs/HSL expression and immunoreactivity. In HepG2 cells incubated with serum or exogenous mevalonate, KMUP-1 (10(−7)∼10(−5) M) reversed HMGR expression by feedback regulation, colocalized expression of ABCA1/apolipoprotein A-I/LXRα/PPARγ, and reduced exogenous geranylgeranyl pyrophosphate/farnesyl pyrophosphate (FPP)-induced RhoA/ROCK II expression. A guanosine 3′,5′-cyclic monophosphate (cGMP) antagonist reversed KMUP-1-induced ROCK II reduction, indicating cGMP/eNOS involvement. KMUP-1 inceased PKG and LDLRs surrounded by LDL and restored oxidized LDL-induced PKA expresion. Unlike simvastatin, KMUP-1 could not inhibit (14)C mevalonate formation. KMUP-1 could, but simvastatin could not, decrease ROCK II expression by exogenous FPP/CGPP. KMUP-1 improves HDL via PPARγ/LXRα/ABCA1/Apo-I expression and increases LDLRs/PKA/PKG/HSL expression and immunoreactivity, leading to TG hydrolysis to lower hepatic fat and body weight.
format Online
Article
Text
id pubmed-4617394
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-46173942015-11-01 Xanthine-based KMUP-1 improves HDL via PPARγ/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss Kuo, Kung-Kai Wu, Bin-Nan Liu, Chung-Pin Yang, Tzu-Yang Kao, Li-Pin Wu, Jiunn-Ren Lai, Wen-Ter Chen, Ing-Jun J Lipid Res Research Articles The phosphodiesterase inhibitor (PDEI)/eNOS enhancer KMUP-1, targeting G-protein coupled receptors (GPCRs), improves dyslipidemia. We compared its lipid-lowering effects with simvastatin and explored hormone-sensitive lipase (HSL) translocation in hepatic fat loss. KMUP-1 HCl (1, 2.5, and 5 mg/kg/day) and simvastatin (5 mg/kg/day) were administered in C57BL/6J male mice fed a high-fat diet (HFD) by gavage for 8 weeks. KMUP-1 inhibited HFD-induced plasma/liver TG, total cholesterol, and LDL; increased HDL/3-hydroxy-3-methylglutaryl-CoA reductase (HMGR)/Rho kinase II (ROCK II)/PPARγ/ABCA1; and decreased liver and body weight. KMUP-1 HCl in drinking water (2.5 mg/200 ml tap water) for 1–14 or 8–14 weeks decreased HFD-induced liver and body weight and scavenger receptor class B type I expression and increased protein kinase A (PKA)/PKG/LDLRs/HSL expression and immunoreactivity. In HepG2 cells incubated with serum or exogenous mevalonate, KMUP-1 (10(−7)∼10(−5) M) reversed HMGR expression by feedback regulation, colocalized expression of ABCA1/apolipoprotein A-I/LXRα/PPARγ, and reduced exogenous geranylgeranyl pyrophosphate/farnesyl pyrophosphate (FPP)-induced RhoA/ROCK II expression. A guanosine 3′,5′-cyclic monophosphate (cGMP) antagonist reversed KMUP-1-induced ROCK II reduction, indicating cGMP/eNOS involvement. KMUP-1 inceased PKG and LDLRs surrounded by LDL and restored oxidized LDL-induced PKA expresion. Unlike simvastatin, KMUP-1 could not inhibit (14)C mevalonate formation. KMUP-1 could, but simvastatin could not, decrease ROCK II expression by exogenous FPP/CGPP. KMUP-1 improves HDL via PPARγ/LXRα/ABCA1/Apo-I expression and increases LDLRs/PKA/PKG/HSL expression and immunoreactivity, leading to TG hydrolysis to lower hepatic fat and body weight. The American Society for Biochemistry and Molecular Biology 2015-11 /pmc/articles/PMC4617394/ /pubmed/26351364 http://dx.doi.org/10.1194/jlr.M057547 Text en Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc. http://creativecommons.org/licenses/by/3.0/ Author’s Choice—Final version free via Creative Commons CC-BY license. Creative Commons Attribution Unported License (http://creativecommons.org/licenses/by/3.0/) applies to Author Choice Articles
spellingShingle Research Articles
Kuo, Kung-Kai
Wu, Bin-Nan
Liu, Chung-Pin
Yang, Tzu-Yang
Kao, Li-Pin
Wu, Jiunn-Ren
Lai, Wen-Ter
Chen, Ing-Jun
Xanthine-based KMUP-1 improves HDL via PPARγ/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss
title Xanthine-based KMUP-1 improves HDL via PPARγ/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss
title_full Xanthine-based KMUP-1 improves HDL via PPARγ/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss
title_fullStr Xanthine-based KMUP-1 improves HDL via PPARγ/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss
title_full_unstemmed Xanthine-based KMUP-1 improves HDL via PPARγ/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss
title_short Xanthine-based KMUP-1 improves HDL via PPARγ/SR-B1, LDL via LDLRs, and HSL via PKA/PKG for hepatic fat loss
title_sort xanthine-based kmup-1 improves hdl via pparγ/sr-b1, ldl via ldlrs, and hsl via pka/pkg for hepatic fat loss
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4617394/
https://www.ncbi.nlm.nih.gov/pubmed/26351364
http://dx.doi.org/10.1194/jlr.M057547
work_keys_str_mv AT kuokungkai xanthinebasedkmup1improveshdlviappargsrb1ldlvialdlrsandhslviapkapkgforhepaticfatloss
AT wubinnan xanthinebasedkmup1improveshdlviappargsrb1ldlvialdlrsandhslviapkapkgforhepaticfatloss
AT liuchungpin xanthinebasedkmup1improveshdlviappargsrb1ldlvialdlrsandhslviapkapkgforhepaticfatloss
AT yangtzuyang xanthinebasedkmup1improveshdlviappargsrb1ldlvialdlrsandhslviapkapkgforhepaticfatloss
AT kaolipin xanthinebasedkmup1improveshdlviappargsrb1ldlvialdlrsandhslviapkapkgforhepaticfatloss
AT wujiunnren xanthinebasedkmup1improveshdlviappargsrb1ldlvialdlrsandhslviapkapkgforhepaticfatloss
AT laiwenter xanthinebasedkmup1improveshdlviappargsrb1ldlvialdlrsandhslviapkapkgforhepaticfatloss
AT cheningjun xanthinebasedkmup1improveshdlviappargsrb1ldlvialdlrsandhslviapkapkgforhepaticfatloss